A Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib With Open-Label Induction, Randomized, Double-Blind Maintenance and Open-Label Long-Term Extension in Pediatric Subjects With Moderately to Severely Active Crohn's Disease and Inadequate Response, Intolerance, or Medical Contraindications to Corticosteroids, Immunosuppressants, and/or Biologic Therapy

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective oral Upadacitinib is in treating moderately to severely active Crohn's Disease in pediatric participants aged 2 to 18 years old who have had inadequate response, loss of response, intolerance, or medical contraindications to corticosteroids, immunosuppressants, and/or biologic therapy.
Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active CD and is being developed for moderate- to severely active CD in pediatric participants. This study is conducted in 2 periods: Period 1 is comprised of two phases: a 12-week open-label induction phase which means that the study doctor and participants know that participants will receive UPA Dose-A (or the adult equivalent based on body weight) followed by a 52-week double-blind maintenance phase meaning that neither the participants nor the study doctors will know which dose of upadacitinib will be given(UPA Dose B or Dose C). Period 2 is a 156-week open-label extension of Period 1. Approximately 110 pediatric participants with moderate to severely active CD will be enrolled at approximately 92 sites worldwide.
Participants will receive upadacitinib oral tablets once daily or oral solution twice daily at approximately the same time each day, with or without food. Participants will have a safety follow up for 30 days after discontinuation from any time point within the study.
There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

开始日期2024-07-26

申办/合作机构

AbbVie, Inc.

NCT06227910 / Not yet recruiting临床3期

A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-Term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Disease (CD) after 12 weeks of treatment. Other aims are to learn how safe and effective DTT is compared to monotherapy for these participants.
All participants will receive DTT (either vedolizumab and upadacitinib or vedolizumab and placebo) for 12 weeks. Participants responding to the treatment will then receive vedolizumab only (monotherapy) for an additional 40 weeks.
During the study, participants will visit their study clinic 15 times.

开始日期2024-07-22

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

100 项与 JAK3 x TYK2 x JAK1 x JAK2 相关的临床结果

登录后查看更多信息

100 项与 JAK3 x TYK2 x JAK1 x JAK2 相关的转化医学

登录后查看更多信息

0 项与 JAK3 x TYK2 x JAK1 x JAK2 相关的专利（医药）

登录后查看更多信息

214

项与 JAK3 x TYK2 x JAK1 x JAK2 相关的文献（医药）

2024-02-13·ACS omega

High-Resolution Structure of RNA G-Quadruplex Containing Unique Structural Motifs Originating from the 5′-UTR of Human Tyrosine Kinase 2 (TYK2)

Article

作者: Orehova, Maria ; Plavec, Janez ; Kocman, Vojc

Tyrosine kinase 2 (TYK2) is a member of the JAK family of nonreceptor-associated tyrosine kinases together with highly homologous JAK1, JAK2, and JAK3 paralogues. Overexpression of TYK2 is associated with several inflammatory diseases, including severe complications during the COVID-19 infection. Since the downregulation of JAK paralogues could lead to serious health consequences or even death, it is critical to avoid it when designing drugs to suppress TYK2. To achieve the required specificity only for TYK2, researchers have recently selectively targeted TYK2 mRNA by developing antisense oligonucleotides. In this work, we expand the target space of TYK2 mRNA by showing that the mRNA adopts tetra-helical noncanonical structures called G-quadruplexes. We identified a TYKwt RNA oligonucleotide from the 5'-UTR of TYK2 mRNA, which adopts multiple different parallel G-quadruplexes that exist at equilibrium. Using NMR spectroscopy, we showed that some of the G-quadruplexes adopt unique structural motifs, mainly due to the formation of a stable GA bulge. Using guanine to uridine substitutions, we prepared the oligonucleotide TYK3_U6, which serves as an excellent model for the bulged G-quadruplexes formed by the TYKwt oligonucleotide. NMR structural analysis, including data on the residual coupling constants (RDC) of the loop regions, unveiled that the studied three-quartet parallel G-quadruplex contains many unusual structural features such as a G(U)A bulge, a guanine residue in the syn conformation, A and U residues stacked on the top G-quartet, and a well-defined adenine from a three-residue long propeller loop oriented in the groove, all of which could be valuable targets for future drug design.

2024-01-26·Journal of the European Academy of Dermatology and Venereology : JEADV

Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta-analysis.

Review

作者: Husein Husein-ElAhmed ; Sara Husein-ElAhmed

Alopecia areata (AA) is an autoimmune disorder that affects the hair follicles, resulting in patchy recurrent hair loss. A large body of evidence has demonstrated the favourable clinical response of the Janus kinase (JAK) inhibitors and biologics, but a lack of comprehensive comparison among these therapies exists in the current literature. This study aimed to compare their efficacy. A systematic review and meta-analysis were performed including randomized trials that report the outcomes of the Severity of Alopecia Tool (SALT)₅₀ and/or the mean change in SALT. These articles were pooled and a network meta-analysis (NAM) was conducted. Based on the surface under the cumulative ranking curve estimates obtained for the mean change in SALT score, baricitinib_4 mg (0.7949656) had the best probability of being the most effective therapy, followed by ritlecitinib_200_50 mg (0.7391906) and ivarmacitinib_4 mg (0.7292594). In contrast, dupilumab, secukinumab, tralokinumab and apremilast were less likely to be effective. Targeting the JAK signalling pathway holds great potential for restoring hair regrowth, albeit the contribution of JAK1, JAK2, JAK3 and TYK2 inhibition to the therapeutic effect on AA is apparently different. Baricitinib_4 mg and ritlecitinib 200_50 mg demonstrated notable efficacy, and both molecules displayed a dose-dependent effect, which is not observed with ivarmacitinib. Further investigations into the specific mechanisms of action of these JAK inhibitors are warranted to elucidate the reasons behind these differences.

2023-11-30·Journal of medicinal chemistry

Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis.

Article

作者: Eunsun Park ; Seolhee Park ; Sun Joo Lee ; Dayeon Jeong ; Hee Jin ; Heegyum Moon ; Boksik Cha ; Dayea Kim ; Seonghee Ma ; Wonhyo Seo ; Seung-Hee Han ; Yun-Sil Lee ; Soosung Kang

Janus kinase 1 (JAK1) plays a pivotal role in regulating inflammation and fibrosis via the JAK/STAT signaling pathway, making it a promising target for associated diseases. In this study, we explored the modification of an N-methyl 1H-pyrrolo[2,3-b]pyridine-5-carboxylate core, leading to the identification of 4-(((2S,4S)-1-(4-trifluoromethyl)-2-methylpiperidin-4-yl)amino)-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (36b) as a highly potent and selective JAK1 inhibitor. Compound 36b exhibited an impressive IC₅₀ value of 0.044 nM for JAK1 and demonstrated remarkable selectivity of 382-fold, 210-fold, and 1325-fold specificity over JAK2, JAK3, and TYK2, respectively. The kinase panel assays further confirmed its specificity, and cell-based experiments established its efficacy in inhibiting JAK1-STAT phosphorylation in human L-132 or SK-MES-1 cells. Pharmacokinetic studies revealed that compound 36b boasts an oral bioavailability exceeding 36%. In a bleomycin-induced fibrosis mouse model, compound 36b significantly reduced STAT3 phosphorylation, resulting in improvement in body weight and reduced collagen deposition, all achieved without significant side effects.

198

项与 JAK3 x TYK2 x JAK1 x JAK2 相关的新闻（医药）

2024-03-21

·精准药物

药物筛选中心对外提供药物活性筛选服务

咨询合作药物筛选中心（暨南大学），隶属于暨南大学药学院公共科研平台。中心拥有Echo550微量液体超声转移工作站等先进的自动化药物筛选仪器，前期支撑的多个激酶抑制剂已经产业转化及发表JMC等高水平论文。目前，筛选中心建有激酶、蛋白酶、HDAC、病毒、细菌等筛选模型，能够开展肿瘤、病毒和细菌感染性疾病等领域相关靶标、细胞、机制的筛选和研究，每天能够完成数万次的新药筛选反应。已建立的药物筛选模型1）激酶：Abl, ABL(M351T), ABL(H396P), ABL(Y253F), ABL1 (E255K), ABL1 (G250E), ABL(Q252H), AKT1, AKT2, AKT3, ALK, ALK5, AuroraA, AuroraB, AXL, BRAF, BRAF(V599E), BTK, DDR1, DDR2, EGFR, EGFR (T790M), EGFR(L858R), EGFR(L861Q), EGFR(T790ML858R), EGFR(D746-750), EGFR(D746-750/T790M), Flt3, FLT3(D835Y), FGFR1, FGFR2, FGFR3, FGFR4, Her2, Her4, KIT, MET, IGF-1R, FGFR1, JAK1, JAK2, JAK3, MAPK10, MAPK14, mTOR, TrkA, TrkB, TrkC,TYK2, KDR, SRC, PDGFRa, PDGFRA(D842V), PDGFRb, RET, ZAK……2）肿瘤细胞模型：近500种肿瘤细胞系和基于Ba/F3的耐药模型。细胞系模型（300种）包括肺癌、胰腺癌、胃癌、肝癌、白血病等肿瘤；Ba/F3模型（200种）包括ABL、EGFR、FGFR、RET、ALK、FLT3、KIT、KRAS等靶点的敏感和耐药模型（支持了5个分子进入临床研究）。3）肿瘤移植瘤模型对外服务1）蛋白和细胞活性；2）体内抗肿瘤药效；3）蛋白表达、小分子-蛋白共晶；4）药代动力学；5）基于化学蛋白质组学的靶标发现;6) 肿瘤靶标及其候选药物的成药性评估。咨询合作

2024-03-18

·动脉网

国产自免，即将深陷百药大战

自免药物市场重新变得充满不确定性。自从修美乐全球销量出现拐点，K药取代修美乐，坐上“药王”宝座，自免药物的开发者们又有了新奔头。在一个非共识的市场里，建立新的秩序，无疑将带来巨大的商业价值。可以看到，全球自免药物市场加速变得拥挤。原本的自免药物巨头没有功成离场，新的跨国药企手持重金加入战局。2023年6月，诺华35亿美元收购IgA肾病药物领先公司Chinook Therapeutics，礼来24亿美元收购DICE Therapeutics，获得其口服IL-17抑制剂等自免用药。在国内，自免新药的开发，相对肿瘤新药，并不算十分热门的领域，但随着越来越多的新靶点被验证，不少企业开始加码布局自免管线。数据显示，国内有数十家新药研发企业，布局了上百条自免新药管线。其中，TNFα和IL-12/IL-23两个自免领域老靶点引发的国产生物类似药竞逐，依然激烈，而JAK、IL-17A等新靶点，则吸引大量创新药企深耕，在研产品数量最多。国产自免药无战事在国内，自免药物市场一直充满不确定性。在生物制剂取代传统抗炎药物，成为自免疾病主流治疗方案的很长一段时间里，这个领域的进口药是干不过国产的。2002年，三生国健的前身中信国健成立。3年后，三生国健推出了靶向TNF-α的重磅产品益赛普，用于治疗类风湿关节炎，2年后新增强直性脊柱炎、银屑病适应症。后来，这款药主导国内自免药市场近15年之久。根据三生国健招股书，2018年至2020年间，益赛普的销售收入是公司营收的主要来源，占比超过99%。2017年9月，益赛普纳入国家医保，进一步推高了销售额。财报显示，2018年，益赛普的销售额达到 11.1 亿元，同比增长 9.7%，占国内TNF-α药物市场份额达到64%。在这个过程中，依那西普的原研药恩利，和在海外卖翻了的TNF-α重磅药物修美乐，一直在国内被益赛普压着打。2010年，恩利和修美乐在国内上市。失去了先发优势的原研明星药，加上高出至少一倍的用药费用，在国内销售十分低迷。2018年，修美乐在样本医院的销售额才刚刚接近2000万元，是益赛普同期销量的1/20。早期国内销售的自免生物制剂数据来源：动脉网根据公开信息整理不过，建立在外部因素之上的市场独占地位，很容易被撼动。转折发生在2019年。2019年，修美乐和类克进入医保，百奥泰的格乐立、海正药业的安健宁获批上市。当年，修美乐、格乐立、安健宁的年治疗费用分别降低到3.35万元、3.01万元和2.99万元，远低于益赛普彼时的6.69万元。2020年，修美乐在样本医院销售额达7008万元，较2019年增长270.76%。2022年，益赛普在TNF-α类药品的市场份额为27%，益赛普的市场份额较去年同期略有下降。2018年至2022年间，国内TNF-α药物市场变化数据来源：三生国健财报实际上，益赛普独占市场背后的另一重原因，在于国内自免药物市场的整体规模一直没有起量。据Frost & Sullivan统计，尽管一直保持着上升趋势，到2022年，国内的自免药物市场规模仍没有突破50亿美元，而同期的全球自免药物市场已经接近1500亿美元。与之形成对比的是，2022年，全球肿瘤药物市场规模约1500亿美元，而国内的这一市场规模已经达到354亿美元。当然，自免药物自有其独特性。自免疾病的患者基数大，治疗周期长，加上药物在适应症之间的拓展性强，本身就很容易出现重磅药物。近年来，随着人们对自免疾病机理研究走向深入，新靶点自免药物逐步改变国内的临床实践和患者习惯，拓宽了自免药物的市场边界。益赛普被迫走下神坛之初，三生国健曾经尝试走出舒适区，去拓展新的疾病领域。但多番尝试后，三生国健又再聚焦自免新药。2023年末，三生国健在财报中表示，将集中全力在自免领域深耕。动脉网注意到，自2023年开始，三生国健陆续减少在其他领域的研发费用，甚至交易其他领域的在研管线。2023年4月，三生国健将公司在研抗肿瘤项目602、609、705、707以及眼科在研药物601A项目独家授予沈阳三生，允许其在中国大陆以及美国开发以上药物。此外，三生国健还将304R项目所产生的所有化合物及其成为药物后的其他在全球范围内的一切权利转让给沈阳三生。白介素闯入者充分挖掘过TNF-α靶向药的潜力之后，扩大自免药物市场规模的希望，落到这个行业的闯入者之上。在国内，IL-17A无疑是最热门的自免新药靶点。除了已经上市的司库奇尤单抗、依奇珠单抗等进口药，从研发进度看，公开信息可以查询的在研IL-17A新药，形成了三个梯队，即以赛立奇单抗和夫那奇珠单抗为代表的NDA药物梯队，由国内的创新药企开发，以QX002N、古莫奇单抗等为代表的已经进入III期临床阶段的管线，和尚处于研发中早期阶段的大量管线。现阶段，全球共上市5款靶向IL-17A/IL-17RA药物，即司库奇尤单抗、依奇珠单抗、尼塔奇单抗、比吉利珠单抗和布罗利尤单抗。其中，司库奇尤单抗、依奇珠单抗和布罗利尤单抗已在国内获批，比吉利珠单抗也已在国内申报上市。作为自免新药，IL-17A/IL-17RA药物极大减少了自免患者的治疗支出，但花费仍然不低。以诺华制药的司库奇尤单抗为例，初始定价每支单价2998元，年治疗费用达4.04万元，而礼来的依奇珠单抗，单支定价4318元，年治疗费用为2.59万元。当然，纳入医保后的治疗价格大幅下降，这是后话。属于国产第一梯队的赛立奇单抗和夫那奇珠单抗，分别由智翔金泰和恒瑞开发，2023年3月和4月，赛立奇单抗和夫那奇珠单抗相继申请在国内上市，成为替代进口IL-17A/IL-17RA药物最有力的竞争者。目前，赛立奇单抗和夫那奇珠单抗都在大人群的临床研究中，表现出了优秀的安全性和有效性。数月前，恒瑞曾公布了夫那奇珠单抗的一项研究结果，评估其在中至重度斑块状银屑病患者中的多中心双盲2期研究（NCT03463187）取得积极结果。数据显示，在第12周，与安慰剂组相比，所有夫那奇珠单抗组的银屑病PASI 75都有所改善，40、80、160和240mg组PASI 75分别为56.8%、65.8%、81.6%和86.5%，而安慰剂组为5.4%；使用夫那奇珠单抗时，达到0或1的医师整体评估反应的患者也更高，40、80、160和240mg组分别为45.9%、47.4%、60.5%和73.0%，而安慰剂组为8.1%。未观察到意想不到的不良反应。本月初，智翔金泰也公布了赛立奇单抗的最新研究数据。数据显示，第12周，200mg赛立奇单抗试验组达到PASI 75的受试者比例为90.7%（安慰剂对照组为8.6%），达到皮损清除/几乎清除（PGA 0/1）的受试者比例为74.4%（安慰剂对照组为3.6%），达到主要临床终点。与此同时，PASI90应答率为74.4%，第52周PASI75应答率96.5%，PASI90应答率为84.1%，PGA0/1应答率为83.7%，保持了高水平的皮损改善，获得持续性的治疗应答。智翔金泰的强势入局，让国产自免一哥之争充满变数。相比之下，国产IL-17A/IL-17RA药物第二梯队的企业颇为庞大，既有国产自免的老大哥三生国健，也有跨界而来的肿瘤新药明星企业君实生物、康方生物。主要的国产IL-17A药物研发进展数据来源：动脉网根据公开信息整理至少7家企业挤在IL-17A药物的III期临床之上，适应症选择高度重叠，破局之争不可谓不激烈。更重要的是，目前冲在研发最前线的创新药企，医学临床和商业渠道能力都不容置疑，也不相上下。作为曾经国内自免生物制剂市场的霸主，三生国健没能跑进IL-17A药物第一梯队，已是遗憾，但基于益赛普建立的，对国内自免疾病治疗特点的理解，和品牌认知，无疑会增加一些胜算。而君实生物和康方生物，作为肿瘤新药领域拓荒者，荃信生物的创始团队也并非新药新兵，他们对新药研发到上市的认知，复制到IL-17A的开发之上，也能减少这个过程的不确定性。从某种意义上讲，或许IL-17A/IL-17RA药物的上市之争，才是国内创新药企业之间，开发能力的第一次真正拼刺刀。弯道超车的JAK抑制剂？以往谈及JAK抑制剂，人们第一反应可能是做肿瘤新药。但从在研项目数量看，JAK是吸引药企数量仅次于TNFα的靶点，热度甚至比IL-17A更高。JAK-STAT信号通路由酪氨酸激酶相关受体、酪氨酸激酶JAK和转录因子STAT组成，由细胞因子刺激的信号转导，参与细胞的增殖、分化、凋亡以及免疫调节等许多重要的生物学过程，是人体内重要的信号通路之一。作为细胞质酪氨酸激酶家族的一员，JAKs共有JAK1、JAK2、JAK3、TYK2四种亚型，亚型之间有重叠的结合对象。其中JAK1、JAK3更多负责免疫调节，而JAK2主要与红细胞和血小板的生成相关。JAK－STAT信号通路与多种自身免疫性疾病的发病机制相关，包括类风湿关节炎、银屑病和炎症性肠病等。从上个世纪90年代全球首个JAK抑制剂被发现以来，全球范围内已经有11款JAK抑制剂原研药获批上市。不同代际的JAK抑制剂数据来源：动脉网根据公开信息整理不同代际 JAK 抑制剂之间的差异，主要体现在对体内信号通路的选择性强弱。第一代JAK抑制剂为非选择性JAK抑制剂，同时阻断多条相关信号通路，缺乏选择性。第二代JAK抑制剂减少了第一代的严重不良反应，选择性地抑制JAK家族成员。到了第三代JAK抑制剂，可高度选择性地结合细胞上的相应结构域，特异性地抑制剂细胞活性。2017年，首款JAK抑制剂登陆国内市场，快速得到临床端认可，JAK抑制剂的市场规模也迅速扩容。数据显示，2022年，国内JAK抑制剂市场规模达到9.43亿元，同比增长222.95%。据弗若斯特沙利文预测，国内JAK抑制剂的销售还将持续增长，到2024年和2030年，市场规模将分别达到100亿、481亿元人民币，2019年至2024年间的复合增长率可以达到92.2%。不过，总体来看，国产JAK抑制剂的自免适应症开发，进展稍逊于IL-17A。动脉网查询发现，现阶段，国内注册申报JAK抑制剂涉及60个品种，313个受理号。其中，在国内JAK抑制剂研发数量TOP10企业中，恒瑞、凌科药业、泽璟生物等，开发进度最靠前。恒瑞开发的SHR0302是一种高选择性的JAK1抑制剂，已在中国获批开展类风湿关节炎、白癜风、溃疡性结肠炎等多种自免疾病的临床试验。其中，SHR0302的斑秃、特应性皮炎、溃疡性结肠炎、类风湿性关节炎、强直性脊柱炎等适应症进展最快，已经进入III期临床试验。泽璟制药开发的盐酸杰克替尼，也已经在进行中高危骨髓纤维化、重症斑秃、中重度特应性皮炎等自免疾病适应症的III期临床试验。除此之外，大多数国产自免JAK抑制剂还出去II期临床试验，或者更早的开发阶段。其中，凌科药业开发的LNK01003，对肠道具有限制性，将用于治疗溃疡性肠炎等疾病的治疗，颇受行业关注，目前，这款药物正在进行II期临床试验。相比IL-17A药物竞争的短兵相接，国产自免JAK抑制剂之争相对温和，但是在定价更低的JAK抑制剂市场，丢了先发优势的国产药物，能否在与进口原研药的竞争中立足，甚至凭借更强的本土化能力弯道超车，答案还不算清晰。无论是在全球还是国内，自免疾病都是第二大的临床用药市场。但与之相对应，药物供给侧的产品体系，尚不算完善。在国内，自免药物体系的缺失则更为明显。自免药物市场规模扩容之下，我们看到，越来越多的国内药企加入、加码这个并不算炙手可热的领域，而谁能笑到最后，我们拭目以待。*封面图片来源：pexels文|王世薇微信|no_th_ing添加时请注明：姓名-公司-职位网站、公众号等转载请联系授权：Rekkiiie近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。动脉网，未来医疗服务平台

财报并购免疫疗法上市批准生物类似药

2024-03-06

·Business Wire

Global Psoriatic Arthritis Drug Landscape Research Report 2024: Comprehensive Insights About 20+ Companies and 25+ Pipeline Drugs - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Psoriatic Arthritis - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriatic Arthritis pipeline landscape is provided which includes the disease overview and Psoriatic Arthritis treatment guidelines. The assessment part of the report embraces, in depth Psoriatic Arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriatic Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Psoriatic Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriatic Arthritis. Psoriatic Arthritis Emerging Drugs Chapters This segment of the Psoriatic Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Psoriatic Arthritis Emerging Drugs Sotyktu: Bristol Myers Squibb Sotyktu (deucravacitinib) is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action, representing a new class of small molecules. It is the first selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Bristol Myers Squibb scientists designed Sotyktu to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-23, IL-12 and Type 1 interferons (IFN), key cytokines involved in the pathogenesis of multiple immune-mediated diseases. Sotyktu achieves a high degree of selectivity by binding to the regulatory domain of TYK2, resulting in allosteric inhibition of TYK2 and its downstream functions. Sotyktu selectively inhibits TYK2 at physiologically relevant concentrations. At therapeutic doses, Sotyktu does not inhibit JAK1, JAK2 or JAK3. Currently, the drug is in the Phase III stage of its development for the treatment of Psoriasis Arthritis. HS-10374: Hansoh BioMedical R&D Company HS-10374 mechanism of action is to inhibit (TYK2) that is tyrosine-kinase 2. TYK2 inhibitors work by blocking the TYK2 protein and the cellular signals that run through it. Those signals can in turn activate other immune proteins and are associated with inflammation. Its route of administration is orally. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Psoriasis Arthritis. si-544: selection si-544, the Companys lead candidate, selectively blocks Kv1.3, a key ion channel expressed disease-associated effector memory T (TEM) cells. Kv1.3 is essential for the chronic activation and proliferation of these cells which escape the control of the immune system and become malignant. TEM cells drive inflammation in many autoimmune diseases, including atopic dermatitis, psoriasis, rheumatoid arthritis, and multiple sclerosis. Currently, the drug is in the Phase I stage of its development for the treatment of Psoriasis Arthritis. Psoriatic Arthritis: Therapeutic Assessment Major Players in Psoriatic Arthritis There are approx. 20+ key companies which are developing the therapies for Psoriatic Arthritis. The companies which have their Psoriatic Arthritis drug candidates in the most advanced stage, i.e. Phase III include, Bristol Myers Squibb. Phases The report covers around 25+ products under different phases of clinical development like Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Molecule Type Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Product Type Drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Psoriatic Arthritis: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Psoriatic Arthritis therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriatic Arthritis drugs. Psoriatic Arthritis Report Insights Psoriatic Arthritis Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Psoriatic Arthritis Report Assessment Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Key Players Pfizer selectION Therapeutics GmbH Jiangsu HengRui Medicine Co., Ltd. Nimbus Lakshmi, Inc. Hansoh BioMedical R&D Company Bio-Thera Solutions Mylan Inc. ACELYRIN Inc. Key Products PF-06700841 si-544 SHR0302 NDI-034858 HS-10374 BAT2506 MYL-1401A ABY-035 For more information about this clinical trials report visit https://www.researchandmarkets.com/r/v6c9p4 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

临床2期临床3期临床1期